India  
 
NewsR.in

United States: Recent Adalimumab Biosimilar Developments - Goodwin Procter LLP

Mondaq Thursday, 12 October 2023
FDA grants interchangeable designation to Pfizer's adaliumumab biosimilar – On October 5, 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has designated ABRILADA...
0
shares		ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

United States: Recent FDA Initiatives To Support Development Of Individualized Cell And Gene Therapies And Rare Disease Therapies - Goodwin Procter LLP

 Last month, FDA issued a Request for Information (RFI) in the Federal Register seeking information and comments from interested stakeholders regarding...
Mondaq